Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 1.60B |
| Revenue (ttm) | 159.74M |
| Net Income (ttm) | -63.85M |
| Shares Out | 56.89M |
| EPS (ttm) | -2.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $27.52 |
| Previous Close | $28.15 |
| Change ($) | -0.64 |
| Change (%) | -2.26% |
| Day's Open | 28.00 |
| Day's Range | 27.45 - 28.46 |
| Day's Volume | 18,381 |
| 52-Week Range | 26.51 - 52.74 |
PLYMOUTH MEETING, Pa., April 12, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
PLYMOUTH MEETING, Pa., April 7, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
Analysts at Goldman Sachs are out with four new Buy recommendations on companies in the oil, biotech and health care businesses.
Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates
WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020
PLYMOUTH MEETING, Pa., March 19, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
PLYMOUTH MEETING, Pa., March 17, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative thera...
PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therap...
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 17, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...
WAKIX ® (pitolisant) Total Revenue of $45.6 Million for Third Quarter of 2020
PLYMOUTH MEETING, Pa. and CHICAGO, Nov. 11, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...
PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 28, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...
PLYMOUTH MEETING, Pa. and CHICAGO, Oct. 14, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innov...
PLYMOUTH MEETING, Pa. and CHICAGO, Aug.
PLYMOUTH MEETING, Pa. and CHICAGO, Aug.
U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week
Harmony shares began trading on the Nasdaq Global Market under the ticker symbol "HRMY" on August 19, 2020.
Harmony Biosciences: Interesting Pharmaceutical Public Offering
PLYMOUTH MEETING, Pa. and CHICAGO, Aug. 18, 2020 /PRNewswire/ -- Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patient...
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvani... [Read more...]
| Industry Biotechnology | IPO Date Aug 19, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol HRMY |
Financial Performance
In 2020, HRMY's revenue was $159.74 million, an increase of 2,564.59% compared to the previous year's $6.00 million. Losses were -$36.94 million, -75.69% less than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is 52.00, which is an increase of 88.99% from the latest price.